1-20 of 21
Dickran Kazandjian, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

Emily Bryer, DO, Alexander Dew, DO, MS, Elizabeth Hill, MD, Elizabeth Gil Ramirez, MD, Candis Morrison, CNP, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Kevin Camphausen, MD, Jennifer Jones, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-136176
Published: 2020
Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136182
Published: 2020
Journal Articles

Evaluation of Whole-Body MRI (WB-MRI) in Smoldering Multiple Myeloma (SMM)

Elizabeth Hill, MD, Baris Turkbey, MD, Evrim Turkbey, MD, Candis Morrison, CNP, PhD, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-136185
Published: 2020
Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Dickran Kazandjian, MD, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Neha Korde, MD, Sham Mailankody, MBBS, Elisabet E. Manasanch, MD, Mary L. Kwok, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Yong Zhang, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Crystal Lu, PharmD, BCOP, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Peter Choyke, MD, Alina Dulau-Florea, MD, Esther Mena, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Nisha Patel, DO, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, Seth M. Steinberg, PhD, William D. Figg, PhD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-136148
Published: 2020
Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1891.
https://doi.org/10.1182/blood-2019-127076
Published: 2019
Journal Articles

Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

David G. Coffey, MD, Ola Landgren, MD PhD, Yuexin Xu, PhD, Dickran Kazandjian, MD, Trevor J. Pugh, PhD, Sacha Gnjatic, PhD, Edus H. Warren, MD PhD, Damian J. Green, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4367.
https://doi.org/10.1182/blood-2019-126222
Published: 2019
Journal Articles

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

Elizabeth Hill, MD, Neha Korde, MD, Sham Mailankody, MBBS, Candis Morrison, CNP, PhD, Alexander Dew, DO, Jennifer Hsu Albert, RN, Katherine Graap, RN, Francesco Maura, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1794.
https://doi.org/10.1182/blood-2019-126952
Published: 2019
Journal Articles

Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia

Tigran Ghazanchyan, MS, Dickran Kazandjian, MD, Donna Przepiorka, MD PhD, Kelly J. Norsworthy, MD, Emma Scott, PhD, Luis Santana-Quintero, PhD, Svetlana Petrovskaya, PhD, Yong Zhang, PhD, Amy Rosenberg, MD, Ashutosh Rao, PhD, Richard Pazdur, MD, Ann T. Farrell, MD, Julia A. Beaver, MD, Vahan Simonyan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2815.
https://doi.org/10.1182/blood-2018-99-116870
Published: 2018
Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Dickran Kazandjian, MD, Neha Korde, MD, Sham Mailankody, MBBS, Yong Zhang, PhD, Jennifer Hsu, RN, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Sneha Divakarla, MHA, Mary L. Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Pallavi Galera, Alina Dulau-Florea, MD, Dalia Salem, MD, Esther Gonzalez, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Katherine R. Calvo, MD PhD, Raul C. Braylan, MD, Constance Yuan, MD PhD, Wyndham H. Wilson, MD PhD, Peter Choyke, MD, Maryalice Stetler-Stevenson, MD PhD, Seth M. Steinberg, PhD, William Figg, PharmD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1957.
https://doi.org/10.1182/blood-2018-99-111712
Published: 2018
Journal Articles

Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma

Venkata Yellapantula, PhD, Malin Hultcrantz, MD PhD, Even H Rustad, Heather J. Landau, MD, Christine Iacobuzio-Donahue, Theresia Akhlaghi, BS, Ido Amit, PhD, Guy Ledergor, MD, Neha Korde, MD, Sham Mailankody, MBBS, Dickran Kazandjian, MD, Akshar Patel, BA, Niccolo Bolli, MD PhD, Elli Papaemmanuil, PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5588.
https://doi.org/10.1182/blood-2018-99-119886
Published: 2018
Journal Articles

FDA Analysis of Racial Demographics in Multiple Myeloma Trials

Vishal Bhatnagar, MD, Nicole Gormley, MD, Dickran Kazandjian, MD, Kirsten Goldberg, MA, Amy E. McKee, MD, Gideon Blumenthal, MD, Ann T. Farrell, MD, Richard Pazdur, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4352.
https://doi.org/10.1182/blood.V130.Suppl_1.4352.4352
Published: 2017
Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4527.
https://doi.org/10.1182/blood.V128.22.4527.4527
Published: 2016
Journal Articles

Longitudinal 18 f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R)

Neha S Korde, MD, Dickran Kazandjian, MD, Mark Roschewski, MD, Sham Mailankody, MD, Malin Hultcrantz, MD, PhD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Peter Choyke, MD, Hani Hassoun, MD, Alexander M. Lesokhin, MD, Nikoletta Lendvai, MDPhD, Eric L. Smith, MD PhD, Ola Landgren, MDPhD, Karen A. Kurdziel, MD, Maria Liza Lindenberg, MD
Journal: Blood
Blood (2016) 128 (22): 3274.
https://doi.org/10.1182/blood.V128.22.3274.3274
Published: 2016
Journal Articles

Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3339.
https://doi.org/10.1182/blood.V128.22.3339.3339
Published: 2016
Journal Articles

Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities

Neha Korde, MD, Sham Mailankody, MD, Mark Roschewski, MD, Malek Faham, Chitra Kotwaliwale, Martin Moorhead, PhD, Mary L Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Rene Costello, Yong Zhang, MD PhD, Adriana Zingone, MD PhD, Debbie Burton, Marcia Mulquin, RN, Ashley Carpenter, RN, Diamond Zuchlinski, RN, Elizabeth Lamping, George Carter, PA, Candis Morrison, Karen Kurdziel, MD, Maria Lindenberg, MD, Roger Kurlander, MD, Irina Maric, MD, Katherine R. Calvo, MD, PhD, Raul C Braylan, MD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C Arthur, MD, Seth M. Steinberg, PhD, William D Figg, PharmD, Peter Choyke, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2105.
https://doi.org/10.1182/blood.V124.21.2105.2105
Published: 2014
Journal Articles

Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study

Ola Landgren, MD PhD, Mark Roschewski, MD, Sham Mailankody, MD, Mary Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Adriana Zingone, MD PhD, Rene Costello, Debra Burton, Yong Zhang, MD PhD, Peter Wu, George Carter, PA, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Ashley Carpenter, RN, Verena Gounden, MD, Candice Morrison, NP, Irina Maric, MD, Katherine R. Calvo, MD, PhD, Raul C. Braylan, MD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C Arthur, MD, Liza Lindenberg, MD, Kurdziel Karen, MD, Peter Choyke, MD, Seth M. Steinberg, PhD, William D Figg, PharmD, Neha Korde, MD
Journal: Blood
Blood (2014) 124 (21): 4746.
https://doi.org/10.1182/blood.V124.21.4746.4746
Published: 2014
Journal Articles

Evaluation Of Circulating Cell-Free VDJ DNA As a Marker For Monitoring Patients With Multiple Myeloma (MM) During Treatment With Carfilzomib, Lenalidomide and Dexamethasone,

Roger Kurlander, MD, Yixin LI, Ph.D., Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Neha Korde, MD, Sham Mailankody, MD, Mary Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Rene Costello, Yong Zhang, PhD, Adriana Zingone, MD, PhD, Peter Wu, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Raul C. Braylan, Mark Roschewski, MD, Ola Landgren, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1868.
https://doi.org/10.1182/blood.V122.21.1868.1868
Published: 2013
Journal Articles

Enzymatic Activities Of Circulating Plasma Proteasomes (cProt) In Newly Diagnosed Multiple Myeloma (NDMM) Patients Undergoing Treatment With Carfilzomib, Lenalidomide and Dexamethasone (CRd)

Elisabet E. Manasanch, MD, Carlos Fernandez de Larrea, MD, Adriana Zingone, Neha Korde, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Dickran Kazandjian, MD, Peter Wu, Rene Costello, Debra Burton, George Carter, PA, Diamond Zuchlinski, RN, Marcia Mulquin, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Mark Roschewski, MD, Ola Landgren, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1877.
https://doi.org/10.1182/blood.V122.21.1877.1877
Published: 2013
Journal Articles

Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients

Ola Landgren, MD, PhD, Sham Mailankody, MD, Mary Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Adriana Zingone, MD, PhD, Rene Costello, Debra Burton, Yong Zhang, PhD, Peter Wu, George Carter, PA, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Raul C. Braylan, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, M.D., Liza Lindenberg, MD, Karen Kurdziel, MD, Peter Choyke, MD, Seth M. Steinberg, PhD, Mark Roschewski, MD, Neha Korde, MD
Journal: Blood
Blood (2013) 122 (21): 1939.
https://doi.org/10.1182/blood.V122.21.1939.1939
Published: 2013
Journal Articles

Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients

Neha Korde, MD, Adriana Zingone, MD, PhD, Mary L Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Sham Mailankody, MD, Rene Costello, Yong Zhang, PhD, Debra Burton, George Carter, PA, Peter Wu, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Raul C. Braylan, Mark Roschewski, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, M.D., Liza Lindenberg, MD, Karen Kurdziel, MD, Pete Choyke, MD, Seth M. Steinberg, PhD, Ola Landgren, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 538.
https://doi.org/10.1182/blood.V122.21.538.538
Published: 2013